Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
Transforming cancer care through collaborative research
Successful partnerships between industry and academia has had a positive impact on cancer drug discovery and development in prostate cancer
Advanced pancreatic cancer: is triple chemotherapy into question?
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
Therapies targeting the TIGIT and STING pathways hold therapeutic promise
Safety and efficacy data of some novel immunotherapy agents are encouraging, but more research is needed to identify biomarkers and the optimal treatment schedule
An ESMO study reveals that poor quality of real-world data from oncology studies is still an issue
Scarcity of prospective data was reported as well as a limited use of real-world evidence as definitive evidence to regulatory approval decisions of targeted therapies in Europe
The future of real-world research is now
ESMO is at the forefront of digital oncology, with some initiatives that support oncologists navigating the emerging opportunities in the field of real-world data research
“Green” prescribing may limit the environmental impact of oncology
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
Early-phase data from targeting HER3 with ADC are encouraging
Some studies presented suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative disease and triple-negative breast cancer
Extended safety information and PROs data support key trial results in metastatic breast cancer
Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant in this setting, despite moderate drop-out rates for PROs